NL301037I2 - Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan - Google Patents
Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan Download PDFInfo
- Publication number
- NL301037I2 NL301037I2 NL301037C NL301037C NL301037I2 NL 301037 I2 NL301037 I2 NL 301037I2 NL 301037 C NL301037 C NL 301037C NL 301037 C NL301037 C NL 301037C NL 301037 I2 NL301037 I2 NL 301037I2
- Authority
- NL
- Netherlands
- Prior art keywords
- solamphetol
- pharmaceutically acceptable
- salt
- acceptable salt
- hydrochloride salt
- Prior art date
Links
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68863805P | 2005-06-08 | 2005-06-08 | |
| PCT/US2006/022407 WO2006133393A1 (en) | 2005-06-08 | 2006-06-07 | Treatment of sleep-wake disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301037I1 NL301037I1 (en:Method) | 2020-04-01 |
| NL301037I2 true NL301037I2 (nl) | 2020-05-12 |
Family
ID=37085728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301037C NL301037I2 (nl) | 2005-06-08 | 2020-03-30 | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8440715B2 (en:Method) |
| EP (1) | EP1890684B1 (en:Method) |
| JP (1) | JP5024635B2 (en:Method) |
| KR (1) | KR101335941B1 (en:Method) |
| CN (1) | CN101217949B (en:Method) |
| AU (1) | AU2006254899B2 (en:Method) |
| BR (1) | BRPI0613697A2 (en:Method) |
| CA (1) | CA2611713C (en:Method) |
| DK (1) | DK1890684T3 (en:Method) |
| ES (1) | ES2435403T3 (en:Method) |
| FR (1) | FR20C1014I2 (en:Method) |
| NL (1) | NL301037I2 (en:Method) |
| PL (1) | PL1890684T3 (en:Method) |
| RU (1) | RU2417077C2 (en:Method) |
| TW (2) | TW201328689A (en:Method) |
| WO (1) | WO2006133393A1 (en:Method) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133393A1 (en) * | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| CA2612672C (en) * | 2005-06-22 | 2014-10-14 | Janssen Pharmaceutica, N.V. | Treatment for sexual dysfunction |
| CN102481274A (zh) * | 2009-06-22 | 2012-05-30 | 爱思开生物制药株式会社 | 治疗或预防疲劳的方法 |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| US8927602B2 (en) * | 2009-11-06 | 2015-01-06 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| WO2011055965A2 (en) | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) * | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) * | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| RU2019114940A (ru) | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| TW201919605A (zh) | 2013-07-18 | 2019-06-01 | 南韓商愛思開生物製藥股份有限公司 | 肥胖之治療 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| WO2016061488A1 (en) * | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
| JP6466792B2 (ja) * | 2015-07-03 | 2019-02-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
| TWI637765B (zh) * | 2016-05-10 | 2018-10-11 | 台灣共振波研發股份有限公司 | Soothing device for attention deficit hyperactivity disorder |
| US10195151B2 (en) * | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| CA3036071A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| EP4316592A3 (en) | 2016-10-06 | 2024-05-01 | Axsome Malta Ltd. | Carbamoyl phenylalaninol compounds and uses thereof |
| JP2020528075A (ja) * | 2017-06-02 | 2020-09-17 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 過度の眠気を処置するための方法および組成物 |
| WO2019027941A1 (en) * | 2017-07-31 | 2019-02-07 | Jazz Pharmaceuticals International Iii Limited | CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US11033214B1 (en) * | 2020-05-19 | 2021-06-15 | United Arab Emirates University | Wearable eye tracking system |
| KR102390194B1 (ko) | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| EP4615426A1 (en) * | 2022-11-07 | 2025-09-17 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| EP4626417A1 (en) * | 2022-11-30 | 2025-10-08 | Axsome Therapeutics | Methods and compositions for improving driving performance |
| WO2025006965A1 (en) | 2023-06-29 | 2025-01-02 | Axsome Therapeutics, Inc. | Methods of administering solriamfetol to lactating women |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2939660A1 (de) * | 1979-09-29 | 1981-04-16 | Basf Ag, 6700 Ludwigshafen | Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| NZ314570A (en) | 1993-06-10 | 2000-11-24 | Lilly Co Eli | Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) * | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) * | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| EP0873308B1 (en) * | 1996-10-10 | 2002-01-02 | SK Corporation | O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts |
| AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| EP1408953B1 (en) * | 2001-02-27 | 2006-04-26 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| ES2262826T3 (es) * | 2001-02-27 | 2006-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad. |
| CA2439478C (en) * | 2001-02-27 | 2010-05-18 | Carlos R. Plata-Salaman | Carbamate compounds for use in preventing or treating movement disorders |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2587481A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Phenylalkylamino carbamates adjunctive therapy for depression |
| WO2006133393A1 (en) * | 2005-06-08 | 2006-12-14 | Sk Holdings Co., Ltd. | Treatment of sleep-wake disorders |
| CA2612672C (en) | 2005-06-22 | 2014-10-14 | Janssen Pharmaceutica, N.V. | Treatment for sexual dysfunction |
| EA019935B1 (ru) | 2005-07-26 | 2014-07-30 | Янссен Фармацевтика Н.В. | Способы лечения алкогольной абстиненции |
| EA200970377A1 (ru) | 2006-10-13 | 2009-10-30 | Янссен Фармацевтика Нв | Композиции фенилалкиламинокарбамата |
| CN102481274A (zh) | 2009-06-22 | 2012-05-30 | 爱思开生物制药株式会社 | 治疗或预防疲劳的方法 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| WO2011055965A2 (en) | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8927602B2 (en) | 2009-11-06 | 2015-01-06 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| KR102005483B1 (ko) | 2012-10-19 | 2019-07-31 | 삼성디스플레이 주식회사 | 박막 트랜지스터 기판 및 그의 수리 방법 |
| RU2019114940A (ru) * | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
-
2006
- 2006-06-07 WO PCT/US2006/022407 patent/WO2006133393A1/en not_active Ceased
- 2006-06-07 JP JP2008515949A patent/JP5024635B2/ja active Active
- 2006-06-07 ES ES06772647T patent/ES2435403T3/es active Active
- 2006-06-07 KR KR1020087000522A patent/KR101335941B1/ko active Active
- 2006-06-07 RU RU2008100019/15A patent/RU2417077C2/ru active
- 2006-06-07 EP EP06772647.1A patent/EP1890684B1/en active Active
- 2006-06-07 PL PL06772647T patent/PL1890684T3/pl unknown
- 2006-06-07 CN CN2006800253545A patent/CN101217949B/zh active Active
- 2006-06-07 CA CA2611713A patent/CA2611713C/en not_active Expired - Fee Related
- 2006-06-07 DK DK06772647.1T patent/DK1890684T3/da active
- 2006-06-07 BR BRPI0613697-4A patent/BRPI0613697A2/pt not_active Application Discontinuation
- 2006-06-07 AU AU2006254899A patent/AU2006254899B2/en active Active
- 2006-06-07 TW TW101130937A patent/TW201328689A/zh unknown
- 2006-06-07 US US11/921,995 patent/US8440715B2/en active Active
- 2006-06-07 TW TW095120134A patent/TWI419681B/zh active
-
2013
- 2013-01-23 US US13/747,508 patent/US8877806B2/en active Active
-
2014
- 2014-08-06 US US14/452,816 patent/US9604917B2/en active Active
-
2017
- 2017-02-15 US US15/433,660 patent/US10351517B2/en active Active
-
2019
- 2019-05-23 US US16/420,834 patent/US20190367448A1/en not_active Abandoned
-
2020
- 2020-03-30 NL NL301037C patent/NL301037I2/nl unknown
- 2020-04-16 FR FR20C1014C patent/FR20C1014I2/fr active Active
- 2020-09-28 US US17/034,564 patent/US11753368B2/en active Active
-
2023
- 2023-08-03 US US18/364,689 patent/US12209059B2/en active Active
-
2024
- 2024-12-13 US US18/979,843 patent/US20250109099A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301037I2 (nl) | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan | |
| NO2024010I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
| NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
| NO2023047I1 (no) | Cedazuridine, or a pharmaceutically acceptable salt thereof | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2022057I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| FIC20240039I1 (fi) | Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301202I1 (nl) | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline | |
| NL301042I2 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301104I2 (nl) | Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat. | |
| NL301065I2 (nl) | Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride | |
| NL301003I2 (nl) | Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300993I2 (nl) | Apalutamide of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300865I2 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
| NL301020I2 (nl) | Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat | |
| NL301177I1 (nl) | tecovirimat of een farmaceutisch aanvaardbaar zout daarvan | |
| NO2022022I1 (no) | Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate | |
| NL301304I2 (nl) | aprocitentan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300990I2 (nl) | Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan | |
| NL300913I2 (nl) | Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride | |
| NL300886I2 (nl) | baricitinib, of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300703I2 (nl) | Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium. | |
| NO2016016I2 (no) | Lesinurad, eller et farmasøytisk akseptabelt salt derav |